SOUTH SAN FRANCISCO, CA--(Marketwire - October 11, 2007) - Novacea, Inc. (NASDAQ: NOVC) today announced the initiation of a Phase 2 trial of AQ4N (banoxantrone), an investigational anti-cancer prodrug, in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
